Conceptus (CPTS) Files Patent Infringement Suit Against Hologic (HOLX)
More News related to CPTS
- Conceptus(R) to Present at the Piper Jaffray 21st Annual Healthcare Conference
- Conceptus(R) to Continue Patent Infringement Suit against Adiana(R) Permanent Contraception System
- SunTrust Downgrades Conceptus (CPTS) to Neutral
- Conceptus(R) to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Essure(R) to Be Highlighted at 18th Annual Congress of the European Society for Gynaecological Endoscopy
More News related to HOLX
- Advanced Image Enhancement Software to be Featured on Hologic Mammography Workstations at RSNA Annual Meeting
- New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity
- Notable Analyst Ratings Changes 11/25: EXXI, IWA, VPRT Upgraded; BNHN, NRG, GTE Downgraded
- Wells Fargo Initiates Coverage on Hologic (HOLX) with an Outperform
- Hologic (HOLX) Could See Pressure As Group Urges Mammograms at 50, Not 40
More News related to Corporate News
- Sidoti & Co Downgrades ICO Inc. (ICOC) to Neutral
- Canaccord Adams Downgrades Enbridge (ENB) to Hold
- Davenport downgrades Yamana Gold Inc. (AUY) to Buy; Valuation Call
- Standpoint Research Downgrades Cemig (CIG) to Hold On Valuation
- Bull vs. Bear: Potash (POT) Upgraded at Dahlman Rose, Downgraded at Desjardins
Conceptus, Inc. (Nasdaq: CPTS) announced that it filed a lawsuit in the United States District Court, Northern District of California against Hologic, Inc., (Nasdaq: HOLX) seeking a declaration by the Court that Hologic's planned importation, use, sale or offer to sell of its forthcoming Adiana Permanent Contraception system, will infringe several U.S. patents owned by Conceptus, including U.S. Patent Nos. 6,634,361, 6,709,667, 7,237,552, 7,428,904 and 7,506,650. Conceptus seeks an injunction prohibiting Hologic from importing, using, selling or offering to sell its Adiana system in the United States.
Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women that is approved for marketing in the United States by the United States Food and Drug Administration (FDA). [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.30
-0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
